Davenport, IOWA – According to the company officials, the treatment would be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention.
Officials say that the AZD7442 treatment may help protect people whose immune systems don’t respond adequately to vaccination.
AstraZeneca says that human trials showed that AZD7442 reduced the risk of developing symptomatic COVID-19 by 77%.
More than three-quarters of the participants had suppressed immune systems and other conditions that made them more susceptible to severe disease.
The drugs are laboratory-made versions of virus-blocking antibodies that help fight off infections.